Revier Therapeutics launches with €6 million seed financing
KHAN Technology Transfer Fund II led funding for Revier’s preclinical cardiometabolic drug programmes, joined by HTGF, VORNvc and Revier Invest Heidelberg.
Revier Therapeutics has launched operations with €6 million in seed financing led by KHAN Technology Transfer Fund II. High-Tech Gründerfonds, VORNvc and private investors through Revier Invest Heidelberg also participated.
The Heidelberg company will use the capital to develop its preclinical pipeline, including programmes for heart failure with preserved ejection fraction and atherosclerotic cardiovascular disease. The financing will also fund the build-out of its operational, scientific and clinical functions.
Use of funds
Develop preclinical cardiometabolic programmes
Build operational, scientific and clinical functions